Evogene Ltd. EVGN
NASDAQ
| 06/30/2026 | 12/31/2025 | 06/30/2025 | 03/31/2025 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | 6.16M | 3.73M | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | 6.16M | 3.73M | |
| Cost of Revenue | -- | -- | 3.39M | 3.59M | |
| Gross Profit | -- | -- | 2.77M | 143.00K | |
| SG&A Expenses | -- | -- | 7.86M | 7.90M | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -10.00K | -- | |
| Total Operating Expenses | -- | -- | 21.39M | 21.67M | |
| Operating Income | -- | -- | -15.23M | -17.94M | |
| Income Before Tax | -- | -- | -10.67M | -12.87M | |
| Income Tax Expenses | -- | -- | 9.00K | 8.00K | |
| Earnings from Continuing Operations | -- | -- | -10.68 | -12.88 | |
| Earnings from Discontinued Operations | -- | -- | -5.22M | -3.55M | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | 1.64M | 1.99M | |
| Net Income | -- | -- | -14.25M | -15.21M | |
| EBIT | -- | -- | -15.23M | -17.94M | |
| EBITDA | -- | -- | -15.46M | -17.72M | |
| EPS Basic | -- | -- | -2.25 | -2.48 | |
| Normalized Basic EPS | -- | -- | -- | -- | |
| EPS Diluted | -- | -- | -2.25 | -2.48 | |
| Normalized Diluted EPS | -- | -- | -- | -- | |
| Average Basic Shares Outstanding | -- | -- | 26.63M | 23.39M | |
| Average Diluted Shares Outstanding | -- | -- | 26.63M | 23.39M | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |